BRONCUS HOLDING CORPORATION Broncus Holding Corporation Share Price
Equities
2216
KYG1609T1022
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.53 HKD | -1.85% |
|
-1.85% | -32.91% |
| 04-22 | Broncus Chairman Resigns; Successor Named | MT |
| 04-19 | Broncus Holding Corporation Announces Changes to Its Board | CI |
| Sales 2023 | 10.26M 80.25M 816M | Sales 2024 * | 13.03M 102M 1.04B | Capitalization | 35.7M 279M 2.84B |
|---|---|---|---|---|---|
| Net income 2023 | -28M -219M -2.23B | Net income 2024 * | - | EV / Sales 2023 | 5.2 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 2.74 x |
| P/E ratio 2023 |
-1.69
x | P/E ratio 2024 * |
-
| Employees | 308 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 77.85% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.85% | ||
| 1 week | -1.85% | ||
| Current month | -7.02% | ||
| 1 month | -7.02% | ||
| 3 months | -22.06% | ||
| 6 months | -47.00% | ||
| Current year | -32.91% |
1 week
0.47
0.54
1 month
0.460.60
Current year
0.460.80
1 year
0.461.85
3 years
0.4618.00
5 years
0.4618.00
10 years
0.4618.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Xu
CEO | Chief Executive Officer | 37 | 21/02/18 |
Yin Kwan Ho
SEC | Corporate Secretary | 47 | 29/08/22 |
Todd R. Cornell
PRN | Corporate Officer/Principal | 54 | 31/07/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ao Zhang
BRD | Director/Board Member | 39 | 28/04/21 |
Pok Man Kam
BRD | Director/Board Member | 75 | 12/09/21 |
Hong Xu
CEO | Chief Executive Officer | 37 | 21/02/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.53 | -1.85% | 6 500 |
| 26/04/24 | 0.54 | +5.88% | 2,500 |
| 25/04/24 | 0.51 | -5.56% | 13,500 |
| 24/04/24 | 0.54 | +3.85% | 14,500 |
| 23/04/24 | 0.52 | -3.70% | 222,000 |
Delayed Quote Hong Kong S.E., April 29, 2024 at 09:08 am
More quotes
Broncus Holding Corp is a China-based investment holding company providing innovative solutions for lung diseases. The Company's business includes providing diagnostic solutions, lung cancer treatment solutions, chronic obstructive pulmonary disease solutions and navigation platforms. The diagnostic solutions pruducts include FleXNeedle, ATV Sheath, ATV Balloon and others. The lung cancer treatment solutions products include InterVapor for lung cancer, H-Marker and others. The chronic obstructive pulmonary disease (COPD) solutions products include InterVapor for COPD and TLD Ablation System. The navigation platform products include Lungpoint, Lungpro, New Generation Navigation Platform and others.
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0677
USD
Average target price
0.137
USD
Spread / Average Target
+102.32%
| 1st Jan change | Capi. | |
|---|---|---|
| -32.91% | 36.37M | |
| -3.22% | 14.6B | |
| -36.36% | 2.71B | |
| -12.35% | 2.44B | |
| -12.00% | 1.51B | |
| -.--% | 1.12B | |
| +41.29% | 518M | |
| +89.74% | 502M | |
| +12.77% | 239M | |
| +1.30% | 183M |
- Stock Market
- Equities
- 2216 Stock
